Article
Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Leukemia - 1 Jul 2012
Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, José-Eneriz E S, Miranda E, Martín-Subero J I, Garate L, Blanco-Prieto M J, García de Jalón J A, Rio P, Rifón J, Cigudosa J C, Martinez-Climent J A, Román-Gómez J, Calasanz M J, Ribera J M, Prósper F
Abstract excerpt
Histone deacetylases (HDACs) have been identified as therapeutic targets due to their regulatory function in chromatin structure and organization. Here, we analyzed the therapeutic effect of LBH589, a class I-II HDAC inhibitor, in acute lymphoblastic leukemia (ALL). In vitro, LBH589 induced dose-dependent antiproliferative and apoptotic effects, which were associated with increased H3 and H4 histone acetylation....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.